Medigene AG in potential €1bn licence and R&D deal

Roivant Sciences and Sinovant Sciences have launched newco Cytovant Sciences, which licenced two T cell-based cancer immune therapies and two development programmes from Medigene AG for commercialisation in the eastern Asian market.

Read more

AMR diagnostic specialist Gradientech raise $4.6m

Gradientech closes a USD 4.6 million rights issue to progress QuickMIC™ diagnostic system for ultra-rapid antibiotics susceptibility testing (AST).

Read more

AgomAb Therapeutics bags €21m Series A financing

AgomAb Therapeutics, a company resulting from a collaboration of argenx SE and growth factor experts from the University of Turin, has completed a €21m Series A financing.

Read more

Novartis acquires inflammasome blocker company IFM Tre

Novartis has aquired all outstanding capital stock and paid US$310m upfront to Boston-based IFM Tre Inc., which commercialises three inflammasome blockers designed to treat chronic inflammatory diseases.

Read more

EMA recommends bluebird’s ?-thalassemia gene therapy

The European Medicines Agency has granted conditional approval for bluebird bio NV’s gene therapy Zynteglo (LentiGlobin BB305) to treat the rare disease transfusion-dependent ?-thalassemia at its first meeting in Amsterdam.

Read more

Polyneuron Pharma raise CHF22.5m in Series A financing

The CHF22.5m Series A financing round of the Swiss specialist for autoimmune diseases was led by Sofinnova Partners and New Enterprise Associates together with contributions of existing investors.

Read more

Genfit prices IPO at $135m

French liver disorder specialist Genfit SA has announced the pricing of its Nasdaq IPO of ADS and European private placement.

Read more

BIO-Europe Spring: Partnering deluxe

The 13th annual BIO-Europe Spring international partnering conference will be held in Vienna, Austria, for the first time, March 25–27, 2019, at the Messe Wien Exhibition and Congress Center. The event is highly regarded among companies across the life science value chain, from large biotech and pharma companies to financiers and innovative startups.

Read more